RG6013: Additional Phase I/II data

Additional data from the open-label, dose-escalation, Japanese Phase I/II ACE002JP trial in 18 patients with severe hemophilia A showed that once-weekly subcutaneous 0.3, 1 and 3 mg/kg doses of ACE910...